Physician
Pandya & Nime MD PA
Pandya & Nime MD PA was paid $349K by Medicaid between Jan 2018 and Oct 2022, across 107 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 35% of everything it billed.
33Billing provider infoPANDYA & NIME MD PA
ROCKLEDGE, FL 32955
ROCKLEDGE, FL 32955
33aNPI1932175502assigned 02/24/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$349K
24GClaims186,488
24DCodes billed107
24AFirst – last monthJan 2018 – Oct 2022
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Florida
Rank by total paid#36 of 207
Median peer was paid$39K
This provider vs. median8.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,798 | $1K | |
| 2019 | 22,063 | $52K | |
| 2020 | 51,850 | $97K | |
| 2021 | 66,843 | $120K | |
| 2022 | 40,934 | $78K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 35% | 3,595 | 2,620 | $120K |
| 80053 | Comprehensive metabolic panel | 19% | 21,344 | 13,417 | $67K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.7% | 5,666 | 3,974 | $20K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.8% | 3,739 | 2,886 | $13K |
| 83880 | 3.3% | 1,498 | 1,095 | $11K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.0% | 26,426 | 15,071 | $10K |
| 87040 | 2.8% | 2,848 | 2,067 | $10K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.3% | 5,623 | 3,077 | $8K |
| 81001 | 2.1% | 7,946 | 7,041 | $7K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 1,048 | 723 | $5K |
| 84702 | 1.5% | 1,207 | 1,036 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 2,161 | 1,907 | $4K |
95 more codes
| 88342 | 1.2% | 700 | $4K | |
| 84484 | 1.1% | 5,923 | $4K | |
| 86780 | <1% | 493 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,563 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 529 | $3K |
| 81025 | <1% | 4,868 | $3K | |
| 83605 | <1% | 2,946 | $3K | |
| 82947 | <1% | 6,710 | $3K | |
| 87186 | <1% | 1,627 | $3K | |
| 83735 | <1% | 7,155 | $2K | |
| 80061 | Lipid panel | <1% | 2,113 | $2K |
| 82962 | <1% | 6,773 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,394 | $2K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 264 | $2K |
| 82746 | <1% | 302 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,459 | $1K |
| 81003 | <1% | 3,956 | $1K | |
| 84703 | <1% | 2,520 | $976.03 | |
| 83690 | <1% | 3,934 | $967.27 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 591 | $956.41 |
| 87081 | <1% | 1,274 | $920.18 | |
| 85730 | <1% | 3,109 | $874.38 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 416 | $829.91 |
| 86850 | <1% | 2,359 | $811.95 | |
| 80320 | <1% | 1,296 | $808.77 | |
| 85610 | <1% | 4,988 | $808.67 | |
| 86703 | <1% | 658 | $795.45 | |
| 86900 | <1% | 3,294 | $781.15 | |
| 85027 | <1% | 2,464 | $767.89 | |
| 88307 | <1% | 15 | $717.67 | |
| 80143 | <1% | 508 | $716.47 | |
| 83020 | <1% | 109 | $692.38 | |
| 80202 | <1% | 475 | $688.54 | |
| 80069 | <1% | 630 | $686.27 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 558 | $647.13 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 84 | $631.30 |
| 82728 | <1% | 599 | $575.84 | |
| 87070 | <1% | 864 | $567.48 | |
| 88313 | <1% | 183 | $522.53 | |
| 82607 | <1% | 534 | $469.01 | |
| 86901 | <1% | 3,314 | $466.43 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 197 | $414.81 |
| 87899 | <1% | 705 | $370.91 | |
| 84600 | <1% | 857 | $346.17 | |
| 85520 | <1% | 264 | $320.45 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 158 | $284.71 |
| 84100 | <1% | 955 | $277.05 | |
| 82247 | <1% | 1,005 | $262.94 | |
| 86769 | <1% | 89 | $251.79 | |
| 82550 | <1% | 704 | $237.26 | |
| 86140 | <1% | 1,020 | $233.09 | |
| 82140 | <1% | 266 | $226.53 | |
| 87088 | <1% | 745 | $221.23 | |
| 87077 | <1% | 456 | $215.54 | |
| 85651 | <1% | 748 | $210.75 | |
| 87205 | <1% | 964 | $201.18 | |
| 83615 | <1% | 590 | $198.88 | |
| 86141 | <1% | 225 | $188.10 | |
| 84132 | <1% | 424 | $172.65 | |
| 84439 | <1% | 383 | $167.77 | |
| 84145 | <1% | 881 | $161.50 | |
| 87075 | <1% | 187 | $154.17 | |
| 86880 | <1% | 182 | $151.24 | |
| 84112 | <1% | 14 | $135.33 | |
| 86738 | <1% | 175 | $133.97 | |
| 86920 | <1% | 22 | $107.44 | |
| 82248 | <1% | 925 | $94.17 | |
| 83550 | <1% | 249 | $90.10 | |
| 86923 | <1% | 59 | $80.61 | |
| 82570 | <1% | 168 | $76.58 | |
| 85018 | <1% | 385 | $67.02 | |
| 85014 | <1% | 356 | $63.35 | |
| 80074 | <1% | 13 | $61.30 | |
| 87340 | <1% | 110 | $52.44 | |
| 83540 | <1% | 205 | $48.99 | |
| 83491 | <1% | 78 | $46.08 | |
| 80076 | <1% | 107 | $42.34 | |
| 80179 | <1% | 476 | $30.57 | |
| 83021 | <1% | 78 | $29.37 | |
| 83516 | <1% | 65 | $26.28 | |
| 82150 | <1% | 96 | $25.22 | |
| 84550 | <1% | 112 | $20.80 | |
| 82776 | <1% | 58 | $18.72 | |
| 82261 | <1% | 78 | $15.84 | |
| 85007 | <1% | 228 | $12.90 | |
| 85041 | <1% | 25 | $11.43 | |
| 84437 | <1% | 58 | $10.56 | |
| 87210 | <1% | 114 | $9.79 | |
| 85384 | <1% | 37 | $7.80 | |
| 82009 | <1% | 34 | $4.80 | |
| 87631 | <1% | 53 | $0.98 | |
| 81329 | 0% | 87 | $0.00 | |
| 81479 | Unlisted molecular pathology procedure | 0% | 82 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 219 | $0.00 |
| 83789 | 0% | 65 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOUIE, SHONDELL (PRESIDENT)